First-line immune checkpoint inhibitors plus chemotherapy in Taiwanese patients with extensive-stage small-cell lung cancer.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) have demonstrated survival benefits when combined with platinum and etoposide (EP) in first-line (1L) treatment for extensive-stage small-cell lung cancer (ES-SCLC). We investigated the real-world outcomes, adverse events (AEs), and prognostic factors of Taiwanese patients with ES-SCLC receiving 1L ICI + EP.

Methods

We analyzed the clinical characteristics, objective response rates, disease control rates (DCR), progression-free survival (PFS), overall survival (OS), and treatment-related AEs of patients with ES-SCLC who received ICI + EP or EP alone as 1L treatment.

Results

A total of 33 patients received ICI + EP, and 199 received EP alone. The 1L ICI + EP group had longer OS than did the 1L EP group (median: 13.9 months

SUBMITTER: Liao YT 

PROVIDER: S-EPMC12637115 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature